Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies
Status:
Completed
Trial end date:
2021-03-31
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability, pharmacokinetic profile and treatment
effect of a new drug known as BGB-3111 in patients with B-Cell Lymphoid Malignancies.